Invention Grant
- Patent Title: Arginine deiminase mutant and preparation and application thereof
- Patent Title (中): 精氨酸脱亚氨酶突变体及其制备及应用
-
Application No.: US13214398Application Date: 2011-08-22
-
Publication No.: US08663967B2Publication Date: 2014-03-04
- Inventor: Yanshan Huang , Jiwan Qiu , Xiaoyu Fu , Min Fan , Yujiao Wang , Yefei Wang
- Applicant: Yanshan Huang , Jiwan Qiu , Xiaoyu Fu , Min Fan , Yujiao Wang , Yefei Wang
- Applicant Address: CN Jiangsu Province
- Assignee: Jiangsu T-MAB Biopharma Co., Ltd.
- Current Assignee: Jiangsu T-MAB Biopharma Co., Ltd.
- Current Assignee Address: CN Jiangsu Province
- Agency: Sinorica, LLC
- Agent Ming Chow
- Main IPC: C12N11/02
- IPC: C12N11/02 ; C12N11/08 ; C12N9/00 ; C12N9/78 ; C12N1/20 ; C12N15/00 ; C07H21/04

Abstract:
The present invention relates to an arginine deiminase mutant with partial lysine-deficient and preparation and application thereof. The arginine deiminase mutant of the present invention has enzymatic activity of degrading arginine into citruline; compared with the arginine deiminase with the amino acid sequence of SEQ ID NO: 1, the amino acid sequence comprises one or more of K9N, T, K59Q, K66R, A, K93E, A, Q, K111R, A, K119Q, L, M, K121Q, I, K122E, L, K126E, S, R, K178I, E, D, K196I, R, K209G, T, D, K243E, V, R, K249D, Q, K263N, Q, K279Y, T, K293R, H, E, K325V, I, K380T, R, E, and K406E, D, S substitutions. Compared with PEG modified natural derived arginine deiminase, the PEG modified arginine deiminase mutant of the present invention retain better bioactivity; and because the quantity of lysine in arginine deiminase is reduced, the PEG modified products are more uniform and can be applied to clinical treatment of hepatoma, melanoma and the like.
Public/Granted literature
- US20130052179A1 ARGININE DEIMINASE MUTANT AND PREPARATION AND APPLICATION THEREOF Public/Granted day:2013-02-28
Information query